Barry J. Simon Immunity Bio, Inc. (IBRX) insider trading activity

Barry J. Simon is Director of ImmunityBio, Inc.. Currently has a direct ownership of 3.24 Million shares of IBRX, which is worth approximately $10.7 Million. The most recent transaction as insider was on Feb 22, 2025, when has been sold 5,453 shares (Common Stock) at a price of $3.42 per share, resulting in proceeds of $18,649. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.24M

3.84% 3M change

3.84% 12M change

Total Value Held $10.7 Million

Barry J. Simon Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 22 2025	SELL Payment of exercise price or tax liability	$18,649 $3.42 p/Share	5,453 Reduced 0.17%	3,243,571 Common Stock
Feb 22 2025	BUY Exercise of conversion of derivative security	-	15,243 Added 0.47%	3,249,024 Common Stock
Jan 22 2025	BUY Exercise of conversion of derivative security	$220,040 $2.0 p/Share	110,020 Added 3.29%	3,233,781 Common Stock
Jan 31 2024	SELL Payment of exercise price or tax liability	$74,235 $3.36 p/Share	22,094 Reduced 0.7%	3,123,761 Common Stock
Jan 31 2024	BUY Exercise of conversion of derivative security	-	57,200 Added 1.79%	3,145,855 Common Stock
Sep 01 2023	BUY Exercise of conversion of derivative security	-	57,199 Added 1.82%	3,088,655 Common Stock
May 25 2021	SELL Open market or private sale	$1,436,574 $16.18 p/Share	88,787 Reduced 2.78%	3,102,507 Common Stock
May 24 2021	SELL Open market or private sale	$339,992 $16.02 p/Share	21,223 Reduced 0.66%	3,191,294 Common Stock
May 21 2021	SELL Open market or private sale	$241,189 $16.09 p/Share	14,990 Reduced 0.46%	3,212,517 Common Stock
May 05 2021	BUY Exercise of conversion of derivative security	$99,692 $1.75 p/Share	56,967 Added 1.73%	3,227,507 Common Stock
Feb 05 2021	SELL Open market or private sale	$510,289 $23.09 p/Share	22,100 Reduced 0.69%	3,170,540 Common Stock
Feb 05 2021	BUY Exercise of conversion of derivative security	$44,200 $2.0 p/Share	22,100 Added 0.69%	3,192,640 Common Stock
Feb 02 2021	SELL Open market or private sale	$1,694,745 $20.65 p/Share	82,070 Reduced 2.52%	3,170,540 Common Stock
Feb 02 2021	BUY Exercise of conversion of derivative security	$164,140 $2.0 p/Share	82,070 Added 2.46%	3,252,610 Common Stock
Jan 28 2021	SELL Open market or private sale	$232,071 $20.53 p/Share	11,304 Reduced 0.36%	3,170,540 Common Stock
Jan 28 2021	BUY Exercise of conversion of derivative security	$22,608 $2.0 p/Share	11,304 Added 0.35%	3,181,844 Common Stock
Jan 27 2021	SELL Open market or private sale	$754,862 $20.61 p/Share	36,626 Reduced 1.14%	3,170,540 Common Stock
Jan 27 2021	BUY Exercise of conversion of derivative security	$73,252 $2.0 p/Share	36,626 Added 1.13%	3,207,166 Common Stock
Dec 22 2020	SELL Open market or private sale	$2,346,500 $18.05 p/Share	130,000 Reduced 3.94%	3,170,540 Common Stock
Dec 22 2020	BUY Exercise of conversion of derivative security	$260,000 $2.0 p/Share	130,000 Added 3.79%	3,300,540 Common Stock

Also insider at

CUE

Cue Biopharma, Inc. Healthcare

Director

VIRX

Viracta Therapeutics, Inc. Healthcare

BJS

Barry J. Simon

Director

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IBRX shares.

Notify only if

Value

Insider Trading

Get notified when an Immunity Bio, Inc. insider buys or sells IBRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to ImmunityBio, Inc.

Track Activities on IBRX

Account